Published in Biochem J on February 01, 1990
Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. Proc Natl Acad Sci U S A (1993) 1.67
Crystal structure of human pepsin and its complex with pepstatin. Protein Sci (1995) 1.21
Two crystal structures for cathepsin D: the lysosomal targeting signal and active site. EMBO J (1993) 1.17
Selective detection of Cathepsin E proteolytic activity. Biochim Biophys Acta (2010) 0.88
CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob Agents Chemother (1993) 0.84
Modification of the substrate specificity of porcine pepsin for the enzymatic production of bovine hide gelatin. Protein Sci (2000) 0.78
Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors. Protein Sci (1997) 0.78
The determination of enzyme inhibitor constants. Biochem J (1953) 27.58
A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors. Biochem J (1972) 4.16
A systematic series of synthetic chromophoric substrates for aspartic proteinases. Biochem J (1986) 1.28
High resolution X-ray analyses of renin inhibitor-aspartic proteinase complexes. Nature (1987) 1.25
Pure human renin. Identification and characterization and of two major molecular weight forms. J Biol Chem (1981) 1.17
Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases. FEBS Lett (1989) 1.16
Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases. J Med Chem (1988) 1.05
On the rational design of renin inhibitors: X-ray studies of aspartic proteinases complexed with transition-state analogues. Biochemistry (1987) 1.04
The amino terminal amino acid sequence of human angiotensinogen. Biochem Biophys Res Commun (1981) 1.03
The pH dependence of the hydrolysis of chromogenic substrates of the type, Lys-Pro-Xaa-Yaa-Phe-(NO2)Phe-Arg-Leu, by selected aspartic proteinases: evidence for specific interactions in subsites S3 and S2. Biochim Biophys Acta (1987) 1.00
Subsite specificity of porcine pepsin. Adv Exp Med Biol (1977) 0.98
Identification of the aspartic proteinases from human erythrocyte membranes and gastric mucosa (slow-moving proteinase) as catalytically equivalent to cathepsin E. Biochem J (1988) 0.95
Novel renin inhibitors containing the amino acid statine. Nature (1983) 0.93
The interaction of aspartic proteinases with naturally-occurring inhibitors from actinomycetes and Ascaris lumbricoides. J Enzyme Inhib (1985) 0.92
Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effect of structure in subsite P3 on inhibition of pepsin. J Med Chem (1982) 0.91
New human renin inhibitors containing an unnatural amino acid, norstatine. J Med Chem (1988) 0.88
X-ray studies of aspartic proteinase-statine inhibitor complexes. Biochemistry (1989) 0.88
Synthesis and biological activity of some transition-state inhibitors of human renin. J Med Chem (1988) 0.86
New inhibitors of human renin that contain novel Leu-Val replacements. J Med Chem (1987) 0.84
Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. J Med Chem (1985) 0.84
CGP 38 560: orally active, low-molecular-weight renin inhibitor with high potency and specificity. J Cardiovasc Pharmacol (1989) 0.82
Penicillopepsin, the aspartic proteinase from Penicillium janthinellum: substrate-binding effects and intermediates in transpeptidation reactions. Biochem Soc Trans (1985) 0.81
Purification and properties of cathepsin D from rat Yoshida ascites hepatoma AH-130. Biol Chem Hoppe Seyler (1988) 0.81
Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo. J Med Chem (1986) 0.80
A highly potent and long-acting oral inhibitor of human renin. Hypertension (1988) 0.80
In vitro inhibition of human renin by statine-containing tripeptide renin inhibitor (ES-1005). J Cardiovasc Pharmacol (1987) 0.78
Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides. J Med Chem (1987) 0.78
Aspartic proteinases and inhibitors for their control in health and disease. Adv Exp Med Biol (1988) 0.77
A novel nonpeptidic, orally active renin inhibitor. Biochem Biophys Res Commun (1989) 0.77
New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 site. J Med Chem (1988) 0.77
Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol (1985) 5.73
The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med (1996) 3.75
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem (1988) 3.04
Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest (1987) 2.41
L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1995) 2.39
The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med (1984) 2.33
Screening for organic mental syndromes in the medically ill. Ann Intern Med (1977) 2.28
Carpal tunnel sonography by the rheumatologist versus nerve conduction study by the neurologist. J Rheumatol (2001) 2.24
Selective chemical catalysis by an antibody. Science (1986) 2.19
HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem Biophys Res Commun (1988) 2.14
The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum (2000) 1.97
Beyond unfavorable thinking: the illness cognition questionnaire for chronic diseases. J Consult Clin Psychol (2001) 1.91
Measurement of the rate of nu(e) + d --> p + p + e(-) interactions produced by (8)B solar neutrinos at the Sudbury Neutrino Observatory. Phys Rev Lett (2001) 1.88
Respiratory syncytial and other viruses associated with respiratory disease in infants. Lancet (1971) 1.86
Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res (2001) 1.76
Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science (1990) 1.75
Sensitive, soluble chromogenic substrates for HIV-1 proteinase. J Biol Chem (1990) 1.70
Conformationally restricted bicyclic analogs of somatostatin. Proc Natl Acad Sci U S A (1978) 1.69
Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res (1997) 1.63
The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol (2000) 1.61
Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry (1995) 1.56
Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc Natl Acad Sci U S A (1986) 1.53
Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature (1997) 1.50
Structural analysis of human proparathyroid hormone by a new microsequencing approach. Nature (1974) 1.50
Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol (2001) 1.46
Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem (1988) 1.45
Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum (1995) 1.44
Viral proteinases: weakness in strength. Biochim Biophys Acta (1990) 1.43
Calcitonin messenger RNA encodes multiple polypeptides in a single precursor. Science (1981) 1.43
A potent cyclic hexapeptide analogue of somatostatin. Nature (1981) 1.42
The amino-acid sequence of the amino-terminal 37 residues of human parathyroid hormone. Proc Natl Acad Sci U S A (1974) 1.37
Sonography and magnetic resonance imaging equivalent for the assessment of full-thickness rotator cuff tears. Arthritis Rheum (1999) 1.36
Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites. Biochemistry (1992) 1.33
Bioactive conformation of luteinizing hormone-releasing hormone: evidence from a conformationally constrained analog. Science (1980) 1.32
4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J Med Chem (2000) 1.30
Comparison of sonography and magnetic resonance imaging for the diagnosis of partial tears of finger extensor tendons in rheumatoid arthritis. Rheumatology (Oxford) (2000) 1.29
A systematic series of synthetic chromophoric substrates for aspartic proteinases. Biochem J (1986) 1.28
Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem (1990) 1.27
Absence of parathyroid hormone messenger RNA in nonparathyroid tumors associated with hypercalcemia. N Engl J Med (1983) 1.27
The N-terminal amino-acid sequence of bovine proparathyroid hormone. Proc Natl Acad Sci U S A (1974) 1.25
Inhibition of pepsin by zymogen activation fragments. Spectrum of peptides released from pepsinogen NH2 terminus and solid phase synthesis of two inhibitory peptide sequences. J Biol Chem (1978) 1.24
High level expression and characterisation of Plasmepsin II, an aspartic proteinase from Plasmodium falciparum. FEBS Lett (1994) 1.23
An unnatural biopolymer. Science (1993) 1.23
Acetamidomethyl. A novel thiol protecting group for cysteine. J Am Chem Soc (1972) 1.23
THE NUTRITIONAL REQUIREMENTS FOR NITROGEN BALANCE IN SURGICAL PATIENTS DURING THE EARLY POSTOPERATIVE PERIOD. J Clin Invest (1947) 1.22
Comparative X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and rapamycin. Acta Crystallogr D Biol Crystallogr (1995) 1.22
Multiple chemical forms of hepatitis B surface antigen produced in yeast. Proc Natl Acad Sci U S A (1985) 1.22
The original "DAS" and the "DAS28" are not interchangeable: comment on the articles by Prevoo et al. Arthritis Rheum (1998) 1.21
Effects of rheumatoid arthritis on employment and social participation during the first years of disease in The Netherlands. Br J Rheumatol (1998) 1.20
Nucleotide sequence of a cloned structural gene coding for a precursor of pancreatic somatostatin. Proc Natl Acad Sci U S A (1980) 1.19
Expression and characterisation of plasmepsin I from Plasmodium falciparum. Eur J Biochem (1997) 1.19
Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis (1996) 1.18
Studies on the total synthesis of an enzyme. V. The preparation of enzymatically active material. J Am Chem Soc (1969) 1.17
Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases. FEBS Lett (1989) 1.16
Highly active cyclic and bicyclic somatostatin analogues of reduced ring size. Nature (1979) 1.16
Anti-VPg antibody precipitation of product RNA synthesized in vitro by the poliovirus polymerase and host factor is mediated by VPg on the poliovirion RNA template. J Virol (1986) 1.15
A super active cyclic hexapeptide analog of somatostatin. Life Sci (1984) 1.14
Antibodies of predetermined specificity to the major charged species of human interleukin 1. Proc Natl Acad Sci U S A (1986) 1.13
Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs (1997) 1.13
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. Ann Rheum Dis (2000) 1.13
Somatostatin-28 encoded in a cloned cDNA obtained from a rat medullary thyroid carcinoma. J Biol Chem (1982) 1.13
Isolation and partial sequence analysis of rat basic somatomedin. Endocrinology (1982) 1.12
Hepatitis A virus 3C proteinase substrate specificity. Biochemistry (1992) 1.12
Exploration of subsite binding specificity of human cathepsin D through kinetics and rule-based molecular modeling. Protein Sci (1993) 1.11
Design of potent and selective human cathepsin K inhibitors that span the active site. Proc Natl Acad Sci U S A (1997) 1.10
Physical organic models for the mechanism of lysozyme action. Adv Enzymol Relat Areas Mol Biol (1973) 1.09
[The practice guideline 'Rheumatoid arthritis' (first revision) from the Dutch College of General Practitioners: a response from the perspective of rheumatology]. Ned Tijdschr Geneeskd (2004) 1.08
Clinically important change in rheumatoid arthritis. J Rheumatol (1996) 1.08
[Diagnosis and treatment of gout: not always simple]. Ned Tijdschr Geneeskd (1996) 1.07
Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum (1993) 1.06
Sequence, expression and modeled structure of an aspartic proteinase from the human malaria parasite Plasmodium falciparum. Mol Biochem Parasitol (1994) 1.06
The prognostic value of the EEG in asphyxiated newborns. Acta Neurol Scand (1995) 1.05
Bacterial arthritis in a district hospital. Clin Rheumatol (1992) 1.05
Quantitative affinity chromatography. Determination of binding constants by elution with competitive inhibitors. Proc Natl Acad Sci U S A (1974) 1.02
Relationship between alpha-helical propensity and formation of the ribonuclease-S complex. J Mol Biol (1975) 1.02
The aspartic proteinase from Saccharomyces cerevisiae folds its own inhibitor into a helix. Nat Struct Biol (2000) 1.01
Humans with traumatic brain injuries show place-learning deficits in computer-generated virtual space. J Clin Exp Neuropsychol (2000) 1.01
The amino acid sequence of antistasin. A potent inhibitor of factor Xa reveals a repeated internal structure. J Biol Chem (1988) 1.00
Versatile approach to encoding combinatorial organic syntheses using chemically robust secondary amine tags. J Med Chem (1996) 1.00
Carboxyl proteinase from Pseudomonas defines a novel family of subtilisin-like enzymes. Nat Struct Biol (2001) 1.00
The pH dependence of the hydrolysis of chromogenic substrates of the type, Lys-Pro-Xaa-Yaa-Phe-(NO2)Phe-Arg-Leu, by selected aspartic proteinases: evidence for specific interactions in subsites S3 and S2. Biochim Biophys Acta (1987) 1.00
Interaction of alpha-dansylated peptide inhibitors with porcine pepsin: detection of complex formation by fluorescence energy transfer and chromatography and evidence for a two-step binding scheme. Biochemistry (1981) 0.99
Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site. Mol Pharmacol (1986) 0.99
The pH dependence of the steady state kinetic parameters for staphylococcal nuclease-catalyzed hydrolysis of deoxythymidine-3'-phosphate-5'-p-nitrophenylphosphate in H 2 O and D 2 O. J Biol Chem (1973) 0.99
Procalcitonin is a glycoprotein. J Biol Chem (1981) 0.99
Is sonography performed by the rheumatologist as useful as arthrography executed by the radiologist for the assessment of full thickness rotator cuff tears? J Rheumatol (1998) 0.99
Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Rheumatol (1998) 0.98
The effect of local heat and cold therapy on the intraarticular and skin surface temperature of the knee. Arthritis Rheum (1992) 0.98
Identification of a receptor for atrial natriuretic factor in rabbit aorta membranes by affinity cross-linking. J Biol Chem (1985) 0.98
Pre-prosomatostatins. Products of cell-free translations of messenger RNAs from anglerfish islets. J Biol Chem (1980) 0.98
Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. J Infect Dis (2001) 0.98
Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition. Biochim Biophys Acta (1997) 0.98
Experimental infection of calves with respiratory syncytial virus. Res Vet Sci (1975) 0.98
A study of the correlation between cyclophilin binding and in vitro immunosuppressive activity of cyclosporine A and analogues. Transplant Proc (1988) 0.98